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Immunochemical Approach for 
Monitoring of Structural Transition 
of ApoA-I upon HDL Formation 
Using Novel Monoclonal Antibodies
Hitoshi Kimura1,2, Shiho Mikawa1,2, Chiharu Mizuguchi1,2, Yuki Horie3, Izumi Morita3, Hiroyuki 
Oyama  3, Takashi Ohgita1, Kazuchika Nishitsuji4, Atsuko Takeuchi5, Sissel Lund-Katz6, 
Kenichi Akaji7, Norihiro Kobayashi3 & Hiroyuki Saito1
Apolipoprotein A-I (apoA-I) undergoes a large conformational reorganization during remodeling of 
high-density lipoprotein (HDL) particles. To detect structural transition of apoA-I upon HDL formation, 
we developed novel monoclonal antibodies (mAbs). Splenocytes from BALB/c mice immunized with 
a recombinant human apoA-I, with or without conjugation with keyhole limpet hemocyanin, were 
fused with P3/NS1/1-Ag4-1 myeloma cells. After the HAT-selection and cloning, we established 
nine hybridoma clones secreting anti-apoA-I mAbs in which four mAbs recognize epitopes on the 
N-terminal half of apoA-I while the other five mAbs recognize the central region. ELISA and bio-layer 
interferometry measurements demonstrated that mAbs whose epitopes are within residues 1–43 or 
44–65 obviously discriminate discoidal and spherical reconstituted HDL particles despite their great 
reactivities to lipid-free apoA-I and plasma HDL, suggesting the possibility of these mAbs to detect 
structural transition of apoA-I on HDL. Importantly, a helix-disrupting mutation of W50R into residues 
44–65 restored the immunoreactivity of mAbs whose epitope being within residues 44–65 against 
reconstituted HDL particles, indicating that these mAbs specifically recognize the epitope region in a 
random coil state. These results encourage us to develop mAbs targeting epitopes in the N-terminal 
residues of apoA-I as useful probes for monitoring formation and remodeling of HDL particles.
Plasma levels of high-density lipoprotein (HDL) cholesterol are well known to be associated with a reduced risk 
of cardiovascular disease1, 2. The anti-atherogenic properties of HDL arise, in part, from its participation in the 
reverse cholesterol transport pathway in which the principal protein, apolipoprotein A-I (apoA-I), plays a central 
role3, 4. It is becoming apparent that the anti-atherogenic effects of HDL are not only dependent on its concentra-
tion in plasma but also on its biological functionality5–7 such as cholesterol efflux capacity from cells8, 9 and apoA-I 
exchangeability in which apoA-I can dissociate from the HDL surface and exchange between HDL particles10, 11.
HDL particles are quite heterogeneous in their size, shape, and lipid and protein compositions12, 13. The hetero-
geneity of HDL particles primarily comes from the highly dynamic structure of apoA-I14, allowing it to adapt mul-
tiple lipid-bound conformations on HDL particles of different sizes and lipid and/or protein compositions3, 15–17. 
Upon HDL formation, apoA-I molecule undergoes a large conformational reorganization in which the opening of the 
N-terminal helix bundle occurs, converting hydrophobic helix-helix interactions to helix-lipid interactions3, 15, 18, 19. 
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The apoA-I molecules in an anti-parallel, double-belt conformation stabilize nascent discoidal HDL particles of 
different sizes with certain segments forming flexible loops that detach reversibly from the surface20–22. In mature 
spherical HDL particles, the apoA-I molecules in the double-belt conformation bend and form a stabilizing trefoil 
scaffold structure16, 23. In addition, such conformational plasticity and flexibility of apoA-I are also thought to be 
associated with its strong amyloidogenic property24, 25.
To discriminate the different apoA-I conformations on HDL particles, native monoclonal antibodies (mAbs) 
generated by hybridoma techniques targeting epitopes distributed along the apoA-I sequence26–32 as well as 
recombinant antibody fragments isolated from phage-displayed libraries33 have been used. A mAb that specifi-
cally recognizes an epitope of apoA-I exposed only in preβ1-HDL (or lipid-poor apoA-I) has been commercially 
available to measure preβ1-HDL concentration in plasma34, 35. In addition, mAbs that specifically recognize oxi-
dized36, 37 or nitrated38 apoA-I in both lipid-free and HDL-bound forms have been developed to assess the distri-
bution and function of modified, dysfunctional apoA-I in plasma as well as in artery wall.
We previously developed a novel method for assessing HDL production from cells based on the 
lipidation-induced hydrophobicity change in apoA-I during HDL formation39. In this assay, we took advantage 
of a significant increase in fluorescence intensity when a fluorescence-labeled helix in apoA-I transfers from 
an aqueous environment to the hydrophobic lipid surface11, 15. In the present study, we focused on the fact that 
apoA-I molecule undergoes a large conformational transition in which the random coil regions both in the 
N-terminal and C-terminal domains form α-helical structure upon lipid binding19, 21, 40, 41. To detect the second-
ary structural transition, we generated a panel of novel mAbs against human apoA-I, and found that mAbs that 
target epitopes in the N-terminal regions of apoA-I can recognize structural transition of apoA-I upon formation 
of HDL particles. The present results suggest that these mAbs may provide useful tools for monitoring formation 
and remodeling of HDL particles.
Results and Discussion
Generation of anti-apoA-I mAbs. Several reports have been published from the 1980s42–45 for genera-
tion of anti-apoA-I mAbs based on the hybridoma method46. In most of these studies, mice were immunized 
with native apoA-I or HDL isolated from human plasma without conjugation with carrier macromolecules. In 
our present study, BALB/c mice, the most common splenocyte donor used for the hybridoma production, were 
immunized with recombinant apoA-I expressed in Esherichia coli (E. coli) cells. Augmentation of its immuno-
genicity was also attempted by conjugation with keyhole limpet hemocyanin (KLH), which is a well-known car-
rier protein.
Ten mice were divided into two groups (A and B), and repeatedly immunized with apoA-I (group A) or 
apoA-I-KLH conjugate (group B) (see Supplementary Information). Unexpectedly, no significant difference was 
observed in serum titer for anti-apoA-I antibodies between the group A and B (Fig. S1, P = 0.93). The first fusion 
experiment was performed using splenocytes from the mouse (#5) (see Fig. S1) in group A. Initial screening by 
the ELISA using microplates coated with the apoA-I-BSA conjugate (see Supplementary Information) showed 
that more than 35 micro-cultures (from a total of 576 cultures) were antibody-positive. However, only two kinds 
of hybridoma clones, each secreting the antibodies Ab#19–17 or Ab#20–7 (Fig. 1), were finally found to be useful 
for this study.
The second fusion used the mice in group B (#2 and #4) as spleen donor. Final immunization was performed 
with apoA-I without KLH conjugation in order to preferentially stimulate B-cell clones that recognize epitopes 
on intact apoA-I molecules. Screening of the initial hybridoma cultures (total 968) were carried out by the ELISA 
using biotin-labeled apoA-I to avoid the possibility that BSA might impair the structures of epitopes inherent to 
native apoA-I. This fusion provided 192 antibody-positive micro-cultures, and finally seven kinds of hybridoma 
clones secreting antibodies that show strongly positive signals in ELISA (Ab#11-5, Ab#66-8, Ab#124-2, Ab#126-
7, Ab#129-9, Ab#176-1, and Ab#187-2). We note that, among these nine mAbs, Ab#19-17 and Ab#20-7 were 
already applied for our recently published studies39, 47, 48.
Fundamental characterization of anti-apoA-I mAbs. Isotyping revealed that all the nine mAbs are 
composed of κ light chains in the combination with γ1 (Ab#20-7, Ab#66-8, Ab#126-7, Ab#129-9, Ab#176-1, and 
Ab#187-2) or γ2a (Ab#11-5, Ab#19-17, and Ab#124-2) heavy chains. Among these mAbs, Ab#20-7, Ab#126-
7, and Ab#187-2 reacted almost equally to the recombinant full-length and the N-terminal 1–83 fragment of 
apoA-I, while the other six mAbs reacted only to full-length apoA-I (Fig. 1). We previously demonstrated that the 
N-terminal 1–83 fragment of apoA-I has a strong propensity to form amyloid fibrils49, 50, which is the hallmark of 
apoA-I amyloidogenesis: for this reason we tested here the reactivities of the mAbs to this fragment. The results 
suggested that these three antibodies recognize epitopes within the N-terminal 1–83 residues whereas the other 
six mAbs should recognize epitopes out of 1–83 residues in apoA-I. We note that all nine mAbs established here 
reacted to native apoA-I purified from human plasma as well as the recombinant apoA-I tested here (Fig. S2).
Epitope determination of anti-apoA-I mAbs. To identify epitopes of anti-apoA-I mAbs we generated, 
a series of deletion mutants of apoA-I lacking N-terminal (∆1–43, ∆44–65, and ∆44–126), central (∆122–143), 
or C-terminal (∆190–243) regions along the molecule were used18. Figure 2A shows the typical results of dot 
blotting of mAbs against apoA-I deletion mutants trapped on the membrane. Ab#19-17, Ab#20-7, Ab#124-2, and 
Ab#187-2 did not recognize ∆44–126, ∆44–65 and ∆44–126, ∆122–143, and ∆1–43 apoA-I, respectively, indi-
cating that epitopes of Ab#19-17, Ab#20-7, Ab#124-2, and Ab#187-2 are within residues 66–121, 44–65, 122–143, 
and 1–43, respectively. Since Ab#19-17 did not recognize the 1–83 fragment of apoA-I (Fig. 1), the epitope of 
Ab#19-17 is considered to be within residues 84–121.
We also examined the reactivity of mAbs against apoA-I deletion mutants by a capture ELISA in which bioti-
nylated apoA-I deletion mutants were coated on ELISA plates. Consistent with the results of dot blotting, each 
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mAb exhibited negligible reactivity only against apoA-I deletion mutants lacking the expected epitope regions 
(Fig. 2B). We also found that the epitope for Ab#126-7 is within residues 44–65 (Fig. S5A) whereas those for 
Ab#11-5, #66-8, Ab#129-9, and Ab#176-1 are within residues 122–143 (data not shown). Based on these results, 
the epitope-containing regions in the apoA-I molecule recognized by each mAbs are schematically summarized 
in Fig. 2C.
Reactivity of mAbs against apoA-I in lipid-free or HDL-bound forms. We next investigated effects 
of lipidation of apoA-I on the reactivity of mAbs. To this end, biotinylated Cys-apoA-I in lipid-free form or 
reconstituted 1-palmitoyl-2-oleoylphosphatidylcholine (POPC) discoidal complexes was immobilized on the 
streptavidin-coated plates. To avoid the possible impairing effects of biotinylation of lysine residues in apoA-I on 
its lipid binding ability51, we used a N-terminally biotinylated Cys-apoA-I because the N-terminal 1–6 residues 
are not involved in formation of α-helical structure of apoA-I on discoidal HDL particles21.
As shown in Fig. 3, all mAbs reacted with lipid-free apoA-I in a concentration-dependent manner, in which 
dissociation constant KD values determined from the fitting to sigmoidal does-response curves were in the 
range of 1.2–2.5 nM (Table 1). In contrast, although Ab#19-17 and Ab#124-2 reacted with apoA-I on discoidal 
complexes similarly to that in the lipid-free form, Ab#20-7 and Ab#187-2 exhibited deficient reactivity against 
disc-bound apoA-I. These results suggest that Abs#20-7 and Ab#187-2 cannot recognize epitope regions of 
apoA-I (within residues 1–43 and 44–65 for Ab#187-2 and Ab#20-7, respectively) in the lipidated state.
To confirm the specificity of Ab#20-7 and Ab#187-2 for recognition of apoA-I, a sandwich ELISA system to 
detect non-labeled apoA-I in the lipid-free or HDL-bound states was established. As a capture antibody, Ab#124-2 
was selected because this mAb recognizes apoA-I both in the lipid-free state and on reconstituted discoidal HDL 
equivalently (Fig. 3). Thus, Ab#19-17, Ab#20-7, and Ab#187-2 were biotinylated and used as detection antibodies. 
These three mAbs reacted with lipid-free apoA-I specifically with KD values of 10–13 nM (Fig. 4A and Table 2). 
In contrast, Ab#20-7 and Ab#187-2 showed obviously defective reactivity to apoA-I in reconstituted discoidal or 
spherical HDL particles whereas Ab#19-17 reacted similarly with apoA-I in either lipid-free or lipidated states 
(Fig. 4B and C). These results are consistent with the notion that Ab#20-7 and Ab#187-2 recognize each epitope 
region of apoA-I only in the lipid-free structure.
These three mAbs, however, recognized plasma HDL, among which Ab#20-7 and Ab#187-2 exhibited less 
binding affinity (KD of 21 nM) than Ab#19-17 (KD of 8.2 nM), as shown in Fig. 4D and Table 2. Bio-layer inter-
ferometry (BLI) analyses using biotinylated mAbs immobilized on streptavidin sensor chips, which allow us to 
Figure 1. Reactivity of the present monoclonal antibodies to full-length and the N-terminal 1–83 fragment 
of apoA-I. Biotinylated full-length apoA-I or its N-terminal 1–83 fragment (0.3 μM) in G-PBS, or PBS (for 
examining the background value) was added to 96-well microplates coated with streptavidin, and then 
incubated for 30 min at 37 °C. After washing the wells with T-PBS, hybridoma supernatants, 500-fold diluted 
with G-PBS, were added to the wells (100 μl/well) and incubated at 37 °C for 30 min. After washing, POD-
conjugated anti-mouse IgG antibody diluted at 1:5000 in G-PBS (100 μl/well) was added and incubated for 
30 min at 37 °C. The wells were washed and bound POD activity was determined colorimetrically (see Materials 
and Methods). ***P < 0.001 versus PBS.
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monitor the association and dissociation kinetics for interactions of mAbs with apoA-I52, also demonstrated that 
the three mAbs exhibit binding behaviors to lipid-free apoA-I and plasma HDL with nanomolar KD values despite 
the deficient binding of Ab#20-7 and Ab#187-2 to reconstituted discoidal HDL particles (Fig. S3 and Table S1). 
The reason why Ab#20-7 and Ab#187-2 recognize plasma HDL might be that apoA-I conformation on plasma 
HDL is partially unfolded, locally different from that in reconstituted HDL particles16. Indeed, circular dichroism 
(CD) spectrometry showed that the secondary structure of apoA-I on plasma HDL was significantly less helical 
than that in reconstituted discoidal or spherical HDL particles (Fig. S4A)53. It should be noted that such difference 
in secondary structure of apoA-I does not necessarily lead to alteration of size distribution of HDL particles16. 
Thus, it is possible that the epitope regions of Ab#20-7 (within residues 44–65) and Ab#187-2 (within residues 
1–43) in apoA-I are partially unfolded in the plasma HDL used in this study.
Effect of a helix-disrupting mutation in apoA-I on mAb recognition activity. Figure 5A shows 
the locations of α-helical segments in lipid-free and discoidal HDL apoA-I determined by hydrogen-deuterium 
exchange analyses21, 54. The transition of apoA-I from the lipid-free to the HDL-bound state is accompanied by a 
conformational change from random coil to α-helix in the N-terminal (residues 45–53 and 66–69), central (resi-
dues 116–146), and C-terminal (residues 179–236) regions. In contrast, crystal structure of C-terminal truncated 
apoA-I demonstrated that the N-terminal 43 residues form a major helix (residues 7–34) and a minor helix (resi-
dues 37–41)55, indicating the possibility that even within residues 7–44 shown as forming α-helix in Fig. 5A, there 
are certain residues to undergo structural transition upon HDL formation. Thus, we hypothesized that Ab#20-7 
and Ab#187-2 cannot recognize epitope region (within residues 44–65 and 1–43, respectively) when forming 
α-helical structure in lipidated apoA-I.
Figure 2. Epitope determination of anti-apoA-I mAbs. (A) ApoA-I deletion variants were blotted on 
nitrocellulose membranes with Ab#19-17, Ab#20-7, Ab#124-2, and Ab#187-2. (B) Ab#19-17, Ab#20-7, 
Ab#124-2, or Ab#187-2 were added to 96-well microplates coated with biotinylated apoA-I deletion variants, 
and detected with anti-mouse IgG antibody. (C) Schematic diagram of the epitope-containing regions in apoA-I 
recognized by mAbs. ***P < 0.001 versus PBS.
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To verify this hypothesis, we focused on the structural transition of residues 44–65 because this region con-
tains an obvious random coil segment in lipid-free apoA-I revealed by both hydrogen-deuterium exchange anal-
ysis (residues 45–53)54 and x-ray crystallography (residues 44–54)55. We first used apoA-I 44–65 synthetic peptide 
in a competitive ELISA because this peptide is predominantly in a random coil structure in solution56. As shown 
in Fig. 5B, binding of Ab#20-7 to lipid-free apoA-I was stoichiometrically competed by apoA-I 44–65 peptide (the 
molar ratio of the 44–65 peptide/apoA-I at IC50 was close to 1.0 mol/mol) whereas no competition was observed 
for Ab#19-17. This clearly indicates that Ab#20-7 recognizes residues 44–65 of apoA-I in a random coil structure.
We next introduced the mutation W50R into apoA-I to disrupt α-helical structure within residues 44–65 when 
the protein is in a lipid-bound state. The W50R mutation, known as an amyloidogenic mutation in apoA-I57, 58, 
places the strongly basic arginine residue into the nonpolar face of the amphipathic α-helix in residues 44–65 
(Fig. 5C left), leading to destabilization of the helical structure. Indeed, far-UV CD measurements demonstrated 
that while apoA-I 44–65 peptide transforms from random coil to α-helical structure upon lipid binding, the 
W50R mutation strongly prevents α-helix formation of the 44–65 peptide (Fig. 5C right).
Figure 5D shows sandwich ELISA for binding of Ab#19-17, Ab#20-7, and Ab#187-2 to the apoA-I W50R 
variant in lipid-free or discoidal HDL forms. It should be noted that although the W50R mutation disrupts local 
helical structure in residues 44–65, it does not significantly affect entire helical structure and protein-lipid inter-
actions in full-length apoA-I59. Indeed, size distributions of discoidal HDL particles formed with full-length 
apoA-I were almost identical in wild-type and the W50R variant (the hydrodynamic diameters were 9.2 ± 2.1 
and 9.4 ± 2.1 nm for wild-type and the W50R apoA-I, respectively). All three mAbs recognize lipid-free apoA-I 
W50R similarly with KD values of 7–10 nM, indicating that the W50R mutation does not affect reactivity of 
three mAbs against lipid-free apoA-I. Importantly, the W50R mutation restored the reactivity of Ab#20-7 against 
apoA-I in discoidal HDL-bound state, whereas almost no effect on the reactivity was observed for Ab#19-17 
Figure 3. Reactivity of mAbs against apoA-I in the lipid-free state or on reconstituted discoidal HDL by ELISA. 
Biotinylated Cys-apoA-I in the lipid-free state or on discoidal HDL were added to 96-well microplates coated 
with streptavidin. After washing, Ab#19-17, Ab#20-7, Ab#124-2, or Ab#187-2 were added to the plates with 
increasing concentrations, and then detected with POD-conjugated anti-mouse IgG antibody.
mAb lipid-free apoA-I discoidal rHDL
Ab#19-17 1.3 ± 0.2 1.3 ± 0.2
Ab#20-7 1.2 ± 0.2 N.D.
Ab#124-2 1.9 ± 0.3 3.8 ± 1.2
Ab#187-2 2.5 ± 0.3 N.D.
Table 1. KD values (nM) for single-antibody ELISA shown in Fig. 3.
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neither Ab#187-2 compared to wild-type apoA-I discoidal HDL (Fig. 4B). These results support the hypothesis 
that Ab#20-7 recognizes residues 44–65 of apoA-I only in a random coil structure.
To further confirm the secondary structure specificity for apoA-I recognition of mAbs, we selected another 
mAb, Ab#126-7 whose epitope is within residues 44–65 in apoA-I (Fig. S5A). Similarly to the case of Ab#20-7, 
this mAb recognized lipid-free apoA-I and plasma HDL well (KD values are 2.7 and 3.6 nM, respectively), but did 
not recognize reconstituted discoidal HDL particles (Fig. S5B). In the W50R variant, in contrast, Ab#126-7 was 
able to recognize discoidal HDL with comparable affinity (KD of 11 nM) to the case of plasma HDL (Fig. S5C). 
Based on these results, it is plausible that anti-apoA-I mAbs having epitopes within residues 44–65 can detect the 
structural transition from random coil to α-helix in apoA-I.
Conclusion
In this report, we have developed novel anti-apoA-I mAbs targeting epitopes within the N-terminal residues in 
apoA-I that undergo structural transition during the formation and maturation of HDL particles. Using pro-
tein engineering with site-directed mutagenesis, we demonstrated that these antibodies specifically recognize the 
epitope region of apoA-I in a random coil state, but not in α-helical structure. In particular, since residues 45–53 
are thought to transform from random coil to α-helical structure upon HDL formation, the mAbs targeting 
residues 44–65 found in this study may have potential as a structure-specific antibody to assess structure and 
function of HDL subpopulations.
Materials and Methods
Buffers. The buffers used in this study, abbreviated as PB, PBS, G-PBS, T-PBS, M-PBS, and PVG-PBS, are 
reviewed in detail in Supplementary Information.
Figure 4. Sandwich ELISA for detection of lipid-free and HDL-bound apoA-I. ApoA-I in the lipid-free state 
(A), on reconstituted discoidal HDL (B) and spherical HDL (C), and human plasma HDL (D) were added to the 
plates coated with Ab#124-2. After washing, biotinylated Ab#19-17, Ab#20-7, or Ab#187-2 were added to the 
plates, and then detected with POD-conjugated streptavidin.
mAb
lipid-free 
apoA-I
discoidal 
rHDL
spherical 
rHDL
plasma 
HDL
Ab#19-17 11 ± 2.9 11 ± 2.2 13 ± 3.0 8.2 ± 0.4
Ab#20-7 13 ± 2.2 N.D. N.D. 21 ± 1.2
Ab#187-2 10 ± 1.0 N.D. N.D. 21 ± 3.2
Table 2. KD values (nM) for sandwich ELISA shown in Fig. 4.
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Preparation of recombinant apoA-I proteins and peptide. To introduce an additional 
N-terminal Cys residue or Trp50Arg mutation in human apoA-I, apoA-I genes were engineered by PCR 
overlap extension method with primers, 5′-GGTACCACGCGGATCCTGTGATGAACCACCACAG-3′ 
and 5′-CTGTGGTGGTTCATCACAGGATCCGCGTGGTACC-3′ for Cys-apoA-I and 5′-AAGCTCCTTG 
ACAACCGTGACAGCGTGACCTCC-3′ and 5′-GGAGGTCACGCTGTCACGGTTGTCAAGGAGCTT-3′ 
for apoA-I Trp50Arg, respectively. The mutant genes obtained, as well as WT apoA-I gene, were subcloned in 
pET32a+ vector (Novagen, Madison, WI) and expressed in E. coli BL21 Star (DE3) to produce the target proteins 
fused with thioredoxin. Cleavage of these fusions with thrombin and subsequent purification18 provided the 
desired apoA-I variants with two extra amino acids, Gly-Ser, at the N-terminus. The purity of apoA-I prepara-
tions was assessed by SDS-PAGE and reverse-phase HPLC (Fig. S6). Protein molecular mass was determined by 
MALDI-TOF MS analysis (Fig. S7). The apoA-I 44–65 peptide was synthesized by the solid-phase method with 
Fmoc chemistry58, 60. These apoA-I variants and peptide were dialyzed from 6 M guanidine hydrochloride solu-
tion into PBS before use.
Figure 5. Effect of W50R mutation in apoA-I on reactivity of mAbs. (A) Locations of α-helical segments in 
lipid-free and discoidal HDL apoA-I21, 54. The cylinders represent α-helices, and the lines indicate random 
coil structure. The crosshatched region (residues 125–158) indicates coexisting helical and disordered loop 
conformations. The epitope-containing segments for Ab#19-17, Ab#20-7, and Ab#187-2 were shown as 
arrowed lines. (B) Competitive ELISA for binding of Abs#19-17 and Ab#20-7 to lipid-free apoA-I (35 nM) with 
increasing concentrations of apoA-I 44–65 peptide. The absorbance at 490 nm in the absence of apoA-I 44–65 
was normalized to 1.0. (C) Helical wheel diagrams of residues 44–65 of apoA-I. Trp-50 is located on the center 
of non-polar face of amphipathic α-helix (left). Far-UV CD spectra of apoA-I 44–65 and W50R variant peptides 
in the absence or presence of egg phosphatidylcholine small unilamellar vesicles (SUVs) (right). (D) Sandwich 
ELISA for binding of mAbs to full-length apoA-I W50R variant in the lipid-free state or on discoidal HDL.
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Generation of monoclonal antibody. All experiments on animals were carried out in accordance with 
guidelines and regulations established in Kobe Pharmaceutical University, and all experimental protocols were 
approved by the Institutional Animal Care and Use Committee. Immunization. Two groups (A and B) of five 
female BALB/c mice (8 weeks of age; Japan SLC, Hamamatsu, Japan) were immunized with the recombinant 
apoA-I (for A) or KLH-conjugated apoA-I (see Supplementary Information) (for B) at two-week intervals. 
Immunogens (25 μg/mouse) were subcutaneously injected with Freund’s complete adjuvant (primary immuni-
zation) or incomplete adjuvant (booster immunizations), emulsified with sterile saline (1:1; 0.2 ml/mouse)61, 62. 
Seven days after the third booster, blood samples were collected from each individual, and the titer of serum 
antibodies was determined by ELISA (see Supplementary Information). For group A, two mice with higher titer 
received intraperitoneal and intrasplenic injections of apoA-I (totally 50 μg) in saline61, 62, and after three days, 
splenocytes therefrom were prepared for cell fusions. For group B, the mice were boosted once more with intact 
apoA-I without KLH conjugation after six months, and serum titer were checked again. Then, apoA-I (50 μg) was 
injected similarly into two mice with higher titer, and splenocytes were prepared. Cell fusion and antibody pro-
duction. Cell fusion46 was performed as described previously61, 62. In brief, splenocytes from the immunized mice 
(1–2 × 108 cells) and 1/5 number of P3/NS1/1-Ag4-1 (NS-1) myeloma cells63 were fused with a 40% polyethylene 
glycol 4000 solution (1 ml)61, 62. The fused cells were cultured in a HAT medium supplemented with 5% hybrido 
hybridoma growth factor (Recenttec, Taipei City, Taiwan) under 5% CO2/95% air at 37 °C for ca. two weeks. 
The antibody-secreting hybridomas were screened by ELISA (see Supplementary Information), expanded in HT 
medium, and then cloned by limiting dilution. The cloned hybridomas were grown in a large scale and culture 
supernatants were used for initial characterization of the mAbs. Selected mAbs (Ab#19-17, Ab#20-7, Ab#124-2, 
Ab#126-7, and Ab#187-2) were produced as ascites fluids by intraperitoneal injection of relevant hybridomas 
into male BALB/c mice pretreated with pristane (0.5 ml/mouse). Mabs therein were partially purified as the IgG 
fractions by a HiTrap Protein G HP column (GE Healthcare Japan, Tokyo, Japan).
Dot blotting. ApoA-I variants blotted on a nitrocellulose transfer membrane were probed with anti-apoA-I 
mAbs followed by POD-conjugated AffiniPure goat anti-mouse IgG antibody (Jackson ImmunoResearch, Inc., 
West Grove, PA) and ECL Prime Western Blotting Detection Reagent (GE Healthcare Japan). Signals were visual-
ized by a C-DiGit Blot Scanner (M&S TechnoSystems, Osaka, Japan) using apoA-I and PBS as control.
Preparation of HDL particles. The total HDL fraction (1.063 < d < 1.21 g/ml) was purified by sequen-
tial ultracentrifugation from normolipidemic human plasma as described previously64. Reconstituted discoidal 
HDL was prepared from POPC and apoA-I by cholate dialysis as reported earlier65. Spherical HDL was prepared 
by co-sonication of POPC, triolein, and apoA-I and isolated by sequential ultracentrifugation as described11. 
Dynamic light scattering measurements on a Zetasizer Nano ZS (Malvern, Malvern, UK) demonstrated the 
homogeneous distribution of discoidal and spherical HDL particles with an average diameter of 10 nm (Fig. S4B).
Biotinylation of apoA-I, apoA-I fragmemt, and mAbs. For biotinylation of Cys-apoA-I, 10-fold 
molar excess of tris(2-carboxyethyl)phosphine HCl (TCEP, Thermo Fisher Scientific) was added to a solution of 
Cys-apoA-I in PBS, and the mixture was incubated for 1.5 h at room temperature to generate sulfhydryl groups. 
Then, 10-fold molar excess of biotin-PEAC5-maleimide (Dojindo, Kumamoto, Japan), dissolved in dimethyl sul-
foxide (DMSO), was added to the reduced Cys-apoA-I in PBS (1 ml), and the mixture was incubated overnight at 
4 °C. For biotinylation of plasma apoA-I, recombinant wild-type and 1–83 fragment of apoA-I, and mAbs, three- 
(for mAbs) or 10-fold (for apoA-I proteins) molar excess of EZ-Link NHS-LC-Biotin (Thermo Fisher Scientific), 
dissolved in DMSO, was added to the target protein in PBS (500 μl), and the mixture was incubated for 2 h at 4 °C. 
After these reactions, unreacted reagents were removed by extensive dialysis at 4 °C in PBS. The degree of labeling 
was determined by SensoLyte HABA biotin quantitation kit (AnaSpec, Fremont, CA).
Single-antibody ELISA. Microwells of the Costar microplates were coated overnight at 4 °C with 25 μg/
ml streptavidin (Funakoshi, Tokyo, Japan) in PBS (100 μl/well), and then blocked by incubating with 1% Block 
Ace (DS Pharma Biomedical, Osaka, Japan) for 60 min at 37 °C. The wells were washed with T-PBS and then 
incubated with biotinylated apoA-I samples diluted with G-PBS (100 μl/well) for 30 min at 37 °C. After washing 
with T-PBS, serially diluted mAbs in G-PBS (0–66.7 nM) were added (100 μl/well) and incubated for 30 min at 
37 °C. The plates were washed again with PBS, and then a POD-conjugated AffiniPure goat anti-mouse IgG anti-
body (Jackson ImmunoResearch), diluted at 1:5000 in G-PBS, was added (100 μl/well) and incubated for 30 min 
at 37 °C. After washing the wells with T-PBS, the bound POD activity was determined colorimetrically by the 
absorbance at 490 nm with absorbance at 620 nm for reference using Infinite 200 PRO microplate reader (Tecan 
Japan, Kawasaki, Japan). ELISA data were fitted by nonlinear regression to a sigmoidal dose-response curve with 
variable slope model using the GraphPad Prism program.
Sandwich ELISA. Microwells of the Costar microplates were coated by incubating overnight at 4 °C with 
100 μl/well of the purified Ab#124-2 in PBS (100 μg/mL), and then blocked with Block Ace. The wells were washed 
with T-PBS and then incubated for 30 min at 37 °C with apoA-I samples (lipid-free, reconstituted discoidal and 
spherical HDL particles, and plasma HDL) at 0.11–350 nM in 100 μl/well, which were serially diluted with G-PBS. 
After washing with PBS (without detergent), biotinylated Ab#19-17, Ab#20-7, or Ab#187-2 in G-PBS (100 μl/
well) was added and incubated for 30 min at 37 °C. Wells were washed with T-PBS, and then incubated for 30 min 
at 37 °C with 1.0 μg/ml POD-conjugated streptavidin (Jackson ImmunoResearch) in G-PBS (100 μl/well). After 
washing, the bound POD activity was measured as described above.
Competitive ELISA. Microwells of the Costar microplates were coated similarly with 10 μg/ml purified 
Ab#19-17 or Ab#20-7, and then blocked with 1% Block Ace. Solutions of a constant amount of biotinylated 
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wild-type apoA-I (35 nM) and varying amounts of apoA-I 44–65 peptide (0.11–350 nM) diluted with G-PBS, 
were mixed with 1:1 by volume, and then 100 μl aliquots of which were added to the wells and incubated for 
30 min at 37 °C. After washing with T-PBS, the POD-conjugated streptavidin was reacted and bound enzyme 
activity was determined as described above.
BLI analysis. BLI experiments were performed using OctetRED 96 system (forteBIO, Pall Life Sciences, 
Menio Park, CA). Microwells in 96 well black polystyrene plates were used as the reaction chamber, and all 
association and dissociation reactions were performed in 200 μl solution. Streptavidin-coated sensor chips were 
dipped in PBS for 600 s for hydration, and the biotinylated mAbs (10 μg/ml) was immobilized on the sensor chips 
for 300 s. BLI sensorgrams were measured in three steps: baseline (60 s), association to the sensor chips (180 s), 
and dissociation from the sensor chips (180 s). ApoA-I in the lipid-free form, on reconstituted discoidal HDL, and 
plasma HDL were set to 44–350 nM in PBS. Signals were monitored and recorded every 0.2 s with sample plates 
being continuously shaken at 1,000 rpm to eliminate mass transport effect. Sensorgram raw data were processed 
by Octet software, and evaluated by BIAevaluation Software Version 4.1 (GE healthcare Japan). The Langmuir 
model for 1:1 binding were used to solve simultaneously for association (kon) and dissociation (koff) rates.
CD spectroscopy. Far-UV CD spectra were recorded from 190 to 260 nm at 25 °C using a Jasco J-1500 spec-
tropolarimeter (JASCO, Tokyo, Japan). The apoA-I solutions of 50 μg/ml in Tris-HCl buffer (pH 7.4) were sub-
jected to CD measurements in a 2 mm quartz cuvette. The α-helical content was derived from the molar ellipticity 
at 222 nm ([θ]222) using the equation: % α-helix = [(−[θ]222 + 3000)/(36000 + 3000)] × 100, assuming that all the 
protein in plasma HDL is apoA-I.
Statistical analysis. Data were analyzed via the unpaired Student’s t test or one-way analysis of variance 
with Dunnett’s test. Results were regarded as significant for P < 0.05. All data are means ± SEM unless otherwise 
noted.
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